Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2025)

Beta Bionics' Current Deferred Revenue history spans 3 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 65.81% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 65.81%, while the annual FY2025 figure was $1.6 million, 65.81% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.6 million at Beta Bionics, up from $1.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.6 million in Q4 2025 and bottomed at $87000.0 in Q4 2023.
  • The 3-year median for Current Deferred Revenue is $1.0 million (2025), against an average of $1.0 million.
  • The largest annual shift saw Current Deferred Revenue soared 979.31% in 2024 before it skyrocketed 65.81% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $87000.0 in 2023, then skyrocketed by 979.31% to $939000.0 in 2024, then surged by 65.81% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Current Deferred Revenue are $1.6 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025).